Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Las Vegas Sands Corp. (LVS) vs Teladoc Health Inc (TDOC) Price & Performance

Las Vegas Sands Corp.Trade
Teladoc Health IncTrade

Price performance (Past 24H)

Key statistics

Las Vegas Sands Corp. vs Teladoc Health Inc — how do they compare? Las Vegas Sands Corp. trades at $45.68 (market cap $29.44B), while Teladoc Health Inc trades at $6.64 (market cap $1.24B). The key difference: Las Vegas Sands Corp. is far larger — about 23.7× Teladoc Health Inc's market cap, and Las Vegas Sands Corp. pays a 2.64% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.

LVSTDOC
Market Cap
$29.44B$1.24B
Sector
Consumer CyclicalHealth
52-Week High
$69.49$9.72
52-Week Low
$44.78$4.47
Enterprise Value
$41.33B$1.50B
Dividend Yield
2.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Las Vegas Sands Corp.

LVS trades at $45.68, up 0.48% on the day, with a bearish technical signal from moving averages but neutral oscillators. Revenue grew to $13.02B in 2025, with net income of $1.63B and a 12.59% margin. Recent earnings show mixed results, beating in Q4 2025 and Q1 2026 but missing in Q2 2026. The company maintains strong profitability metrics, including a 48.52% gross margin and 134.29% ROE. Positive news includes ESG recognitions and community initiatives, supporting a stable operational outlook.

The stock presents a buy opportunity with a consensus price target of $60.75, implying 33% upside, backed by 59% analyst buy ratings. Risks include high debt levels, with a debt-to-asset ratio of 73.15% in 2025, and sensitivity to macroeconomic factors affecting the gaming and tourism sectors. Institutional sentiment remains positive, but investors should monitor debt management and regional economic conditions for sustained growth.

Teladoc Health Inc

TDOC trades at $6.66, down 5.93% amid bearish technical signals and negative sentiment following a Q2 2026 revenue miss and lowered full-year guidance. The stock shows weak profitability with a net income margin of -7.13% but trades below book value with a P/B of 0.94. Recent news highlights multiple law firm investigations into potential securities violations, adding to investor concerns.

The outlook remains challenging with revenue pressures in the BetterHelp segment and ongoing losses, though cost controls in Integrated Care provide some support. Analyst consensus is mixed with a $8.88 price target but high hold ratings, indicating cautious optimism amid significant operational and legal risks.

Returns comparison

Trailing returns across standard periods

About Las Vegas Sands Corp.

Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.

Read more on LVS

About Teladoc Health Inc

Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.

Read more on TDOC